"I say this unequivocally, I am not satisfied with Unilever's recent value creation for its shareholders."
Almost a month after his failed attempt to buy the consumer health branch of GSK for 60 billion euros and the fall of 10% of the action in two days, Alan Jope makes his mea culpa.
Despite Unilever's record growth for ten years (+ 4.5% in 2021) driven by price increases, the share price of the owner of Skip, Omo, Axe, Ben & Jerry's and Dove shows a decline of 8% over six months.
On the occasion of the publication of its annual results on Thursday, the boss of the consumer giant clarified its strategy.
No question of taking the path of a mega-merger to accelerate its strategic shift towards health, beauty and hygiene, warns the CEO.
Unilever will accelerate well in these categories, but through organic growth or targeted portfolio adjustments.
Read also
Unilever is making its work revolution
“We have engaged in extensive discussions with our shareholders in recent…
This article is for subscribers only.
You have 67% left to discover.
Cultivating your freedom is cultivating your curiosity.
Keep reading your article for 1€ the first month
I ENJOY IT
Already subscribed?
Login